Regulatory T cells (T reg cells) have a crucial role in the immune system by preventing autoimmunity, limiting immunopathology, and maintaining immune homeostasis 1 . However, they also represent a major barrier to effective anti-tumour immunity and sterilizing immunity to chronic viral infections 1 . The transcription factor Foxp3 has a major role in the development and programming of T reg cells 2,3 . The relative stability of T reg cells at inflammatory disease sites has been a highly contentious subject 4-6 . There is considerable interest in identifying pathways that control the stability of T reg cells as many immune-mediated diseases are characterized by either exacerbated or limited T reg -cell function. Here we show that the immune-cell-expressed ligand semaphorin-4a (Sema4a) and the T reg -cell-expressed receptor neuropilin-1 (Nrp1) interact both in vitro, to potentiate T reg -cell function and survival, and in vivo, at inflammatory sites. Using mice with a T reg -cell-restricted deletion of Nrp1, we show that Nrp1 is dispensable for suppression of autoimmunity and maintenance of immune homeostasis, but is required by T reg cells to limit anti-tumour immune responses and to cure established inflammatory colitis. Sema4a ligation of Nrp1 restrained Akt phosphorylation cellularly and at the immunologic synapse by phosphatase and tensin homologue (PTEN), which increased nuclear localization of the transcription factor Foxo3a. The Nrp1induced transcriptome promoted T reg -cell stability by enhancing quiescence and survival factors while inhibiting programs that promote differentiation. Importantly, this Nrp1-dependent molecular program is evident in intra-tumoral T reg cells. Our data support a model in which T reg -cell stability can be subverted in certain inflammatory sites, but is maintained by a Sema4a-Nrp1 axis, highlighting this pathway as a potential therapeutic target that could limit T reg -cell-mediated tumour-induced tolerance without inducing autoimmunity.
in vitro. a, Transwell suppression assay in which T reg cells were co-cultured in the top chamber of a transwell plate with anti-CD3-and anti-CD28-coated beads in the presence or absence of CD4 1 or CD8 1 T conv cells that had been transfected previously with scrambled or siRNA to Sema4a. Proliferation of T conv cells stimulated with anti-CD3-and anti-CD28-coated beads in the bottom chambers was measured by [ 3 H]-thymidine uptake. b, Transwell suppression assay with T reg cells co-cultured in top chamber with CD4 1 , CD8 1 or CD11c 1 cells including anti-Sema4a or its isotype control. c, Transwell suppression assay in which T reg cells were co-cultured in the absence of T conv cells but in the presence of beads coated with Sema4a-IgG1 or its isotype control. d, ELISAbased binding assay in which plates coated with Nrp1 were incubated with Sema4a-IgG1 or its isotype control in the presence of various blocking antibodies. Sema4a-IgG1 was detected using an isotype specific antibody. e, Transwell suppression assay in which T reg cells were purified by flow cytometry from Foxp3 Cre or Nrp1 f/f Foxp3 Cre mice. f, Annexin V-7-AAD staining of T reg cells stimulated for 48 h in vitro in the presence of Sema4a-IgG1 or its isotype control. Results represent the mean of five independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001 by unpaired t-test. Error bars indicate s.e.m. antibody blockade, we confirmed that Sema4a was necessary for T conv and dendritic cells to potentiate T reg -cell-mediated transwell suppression ( Fig. 1a, b and Supplementary Fig. 2a-e ). Sema4a is also sufficient to potentiate suppression, as T reg cells cultured in the presence of beads coated with a Sema4a-immunoglobulin-G1 (IgG1) fusion protein, instead of fixed T conv cells, potentiated transwell suppression (Fig. 1c ). In contrast, soluble Sema4a-IgG1 inhibited T conv -cell-potentiated, T reg -cellmediated transwell suppression ( Supplementary Fig. 2f ). These data demonstrate that Sema4a is required and sufficient to potentiate T regcell function by soluble factors in vitro. Nrp1 is a homogeneously expressed marker of thymically derived T reg cells, and has also been shown to bind Sema3a, which shares homology with Sema4a, and vascular endothelial growth factor (VEGF) in mediating neural axon growth and angiogenesis ( Supplementary Fig. 3a ) [10] [11] [12] [13] . We therefore proposed that Nrp1 functions as a receptor for Sema4a on T reg cells. Sema4a could directly and specifically bind to Nrp1, albeit with slightly lower avidity to Sema3a, as demonstrated in an enzymelinked immunosorbant assay (ELISA)-based binding assay with recombinant Nrp1 and Sema family proteins and blocking antibodies to Nrp1 or Sema4a ( Fig. 1d and Supplementary Fig. 3b-d ). We bred mice harbouring a loxP-flanked ('floxed') Nrp1 gene (Nrp1 f/f ) to mice expressing a yellow fluorescent protein (YFP)-codon-improved Cre (iCre) fusion protein driven by an IRES following Foxp3 (Foxp3 YFP-iCre , which we refer to as Foxp3 Cre ) to obtain a T reg -cell-restricted deletion of Nrp1 (Foxp3 YFP-iCre 3 Nrp1 f/f , which we refer to as Nrp1 f/f Foxp3 Cre ). Sema4a-IgG1 also bound to control but not Nrp1-deficient T reg cells in a flow cytometric assay ( Supplementary Fig. 3e ). These data support a direct interaction between Nrp1 and Sema4a.
Although Nrp1-deficient T reg cells develop normally and can suppress in a 'classical' contact-dependent suppression assay ( Supplementary   Fig. 4a ), they were unable to suppress across a transwell membrane in the presence of either T conv cells or Sema4a-IgG1-coated beads ( Fig. 1e ). Transwell suppression can be blocked by anti-Nrp1 and, as reported previously, is dependent on interleukin-10 (IL-10) and IL-35 (Supplementary Fig. 4b-d ) 8 . Sema4a-Nrp1 ligation substantially reduced cell death and modestly increased proliferation, and, although singlecell levels of IL-10 and IL-35 did not change, increased survival resulted in greater amounts of IL-10 and IL-35 in Sema4a-treated T reg -cell cultures ( Fig. 1f and Supplementary Fig. 4e -i). Expression of NRP1 on human T reg cells has been a contentious subject 14, 15 . We observed sustained NRP1 expression, albeit modest, on optimally suppressive T reg cells that could mediate transwell suppression in response to human SEMA4A in a NRP1-dependent manner ( Supplementary Fig. 5 ). Taken together, these data suggest Sema4a-Nrp1 interaction promotes T reg -cell survival and function.
Nrp1 f/f Foxp3 Cre mice did not show any autoimmune phenotype for at least 16 months after birth (data not shown). In addition, the capacity of Foxp3 Cre and Nrp1 f/f Foxp3 Cre T reg cells to limit the development of the autoimmune sequelae caused by Foxp3 deletion was comparable ( Supplementary Fig. 6 ), suggesting that maintenance of immune homeostasis and prevention of autoimmunity may not require Nrp1 signalling.
We reasoned that Nrp1 signalling may regulate T reg -cell function under inflammatory conditions. T reg cells are recruited to and are induced by tumour cells, which consequently hamper protective anti-tumour immunity 16 . Foxp3 DTR-GFP mice, which allow for conditional T reg -cell deletion following diphtheria toxin treatment 17 , can clear MC38 adenocarcinoma, EL4 thymoma, and B16 melanoma tumours when treated with diphtheria toxin at the time of inoculation, although they invariably succumb to autoimmune disease ( Fig. 2a-c) . Notably, Nrp1 f/f Foxp3 Cre mice showed reduced, delayed tumour growth and increased survival, 
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particularly with B16 melanoma, without any detectable autoimmune consequences ( Fig. 2a -c and data not shown). In wild-type C57BL/6 mice, blockade of this pathway using Sema4a monoclonal antibody, Nrp1 monoclonal antibody (which does not block Nrp1-VEGF interaction), and Sema4a-IgG1 (which acts as a soluble antagonist), significantly decreased tumour growth ( Fig. 2d-f and Supplementary  Fig. 2f , 3b, c). Nrp1-deficient T reg cells also failed to suppress clearance of B16 lung metastases, even with very high tumour cell inoculates ( Fig. 2g and Supplementary Fig. 7a ). Nrp1 f/f Foxp3 Cre mice displayed increased intratumoral CD8 1 T cells, particularly in the IFN-c 1 IL-2 1 TNF-a 1 tumoricidal subset ( Fig. 2h ) 18 . Although we originally presumed the source of Sema4a would be tumour-infiltrating T cells and conventional dendritic cells, the majority of Sema4a 1 cells infiltrating tumours were plasmacytoid dendritic cells (57.4% of intratumoral Sema4a 1 cells), consistent with previous suggestions highlighting mechanistic links between T reg cells and plasmacytoid dendritic cells in mediating tumourinduced tolerance ( Fig. 2i and Supplementary Fig. 7b , c) 19 . Indeed, plasmacytoid dendritic cells can potentiate T reg -cell function in vitro in a Sema4a-Nrp1-dependent manner ( Supplementary Fig. 7d ). Treatment with Sema4a-IgG1 also resulted in an increased number of intratumoral CD8 1 T cells, consistent with observations with Nrp1 f/f Foxp3 Cre mice ( Supplementary Fig. 7e ). Nrp1-deficient T reg cells also fail to cure established inflammatory colitis, suggesting that the utilization of this pathway is not restricted to the tumour microenvironment (Supplementary Fig. 8 ). Thus, although Nrp1 seems to be dispensable for regulating immune homeostasis, it is required for maximal T reg -cellmediated control of inflammatory environments. We next sought to determine the signalling pathway downstream of Nrp1. Given the importance of limiting Akt-serine/threonine-protein kinase mTOR signalling in T reg -cell function, and previous suggestions that Nrp1 modulates Akt signalling, we proposed that Nrp1 inhibits Akt function in T reg cells [20] [21] [22] . Indeed, T-cell receptor (TCR)-and CD28activation-induced whole-cell Akt-mTOR signalling (as determined by phosphorylation of Akt and S6K1) was reduced to baseline levels in freshly isolated T reg cells (as well as 47-54% in IL-2-expanded T reg cells) by Sema4a-mediated Nrp1 ligation ( Supplementary Fig. 9a, b ). Furthermore, T reg -cell activation on stimulatory lipid bilayers containing Sema4a-IgG1, but not an isotype control, recruited Nrp1 to the immunologic synapse and inhibited immunologic synapse Akt phosphorylation, while sparing global immunologic synapse tyrosine 
Cytokines/cytotoxicity/other regulators (ratio of total) **** **** RESEARCH LETTER phosphorylation ( Fig. 3a and Supplementary Fig. 9c, d) . Retroviral overexpression of a dominant-negative Akt mutant 23 in T reg cells expanded with IL-2 limited the requirement for Nrp1 ligation, at least in transwell suppression assays, suggesting that Akt may be a dominant pathway that limits T reg -cell transwell suppression ( Fig. 3b and Supplementary Fig. 9e ). As immunologic synapse phosphorylated-Akt diminution in response to Sema4a was rapid, we reasoned that Nrp1 recruits the phosphatase PTEN to the immunologic synapse, restraining Akt-mTOR signalling 24 . Nrp1 constitutively bound PTEN in resting T reg cells, which was reduced upon activation but maintained in the presence of Sema4a-Nrp1 interaction (Fig. 3c ). PTEN-deficient T reg cells failed to inhibit Akt phosphorylation at the immunologic synapse in the presence of Sema4a, and failed to suppress across a transwell membrane in response to Sema4a-or T conv -cell-mediated potentiation ( Fig. 3d and Supplementary Fig. 10a, b ). Nrp1 has a small cytoplasmic domain consisting of an evolutionarily conserved PDZ domainbinding motif (carboxy-terminal amino acid sequence: Ser-Glu-Ala) 25 . Nrp1 mutants lacking this motif could not inhibit Akt phosphorylation at the immunologic synapse or recruit PTEN ( Fig. 3e and Supplementary Fig. 10c, d) . Activated Akt can phosphorylate Foxo transcription factors, promoting their exclusion from the nucleus 26 . Foxo transcription factors are critical for T reg -cell development, through interaction with Foxp3 as well as inducing several T reg -cell signature genes [26] [27] [28] . Indeed, Sema4a-IgG1 limited the activation-induced nuclear export of Foxo3a (Fig. 3f ). We propose that, during activation, Nrp1 ligation restrains Akt phosphorylation through PTEN, facilitates Foxo nuclear localization, and thereby potentiates T reg -cell function. Gene-expression analysis revealed an Nrp1-induced transcriptional profile that was consistent with promoting T reg -cell survival, stability and quiescence, and that was similar to a Foxo-dependent transcriptional signature (Fig. 3g) [26] [27] [28] . Gene Ontology and Gene Set Enrichment Analysis revealed that Nrp1 ligation modulated multiple pathways and programs, including the IL-2-and IL-7-related transcriptional programs, repression of cytokine transcripts and modulated Foxp3 targets ( Fig. 3g, Supplementary Fig. 11-13 , and Supplementary Tables 1  and 2 ). Of particular interest was the stabilization of the transcription factor Kruppel-like Factor 2 (KLF2) (and its targets Sell, Ccr7, Il7r), the T reg -cell regulator Helios (Ikzf2; also known as IKAROS family zinc finger 2), and the anti-apoptotic protein Bcl2, accompanied by a concomitant repression of the lineage defining transcription factors Eomes, IRF4 and RORct (nuclear receptor ROR-ct, encoded by Rorc), suggesting a role for Nrp1 in stabilizing the T reg -cell program and repressing terminal differentiation ( Fig. 3g and Supplementary Fig. 13b-d) .
Finally, we sought to determine whether the molecular fingerprints of Nrp1 signalling could be observed in vivo. Tumour-infiltrating T regcells restrained Akt phosphorylation in an Nrp1-dependent manner (Fig. 4a) . Likewise, tumour-infiltrating T reg cells showed Nrp1-dependent upregulation of Helios and downregulation of IRF4 and RORct ( Fig. 4b and Supplementary Fig. 14a, b ). This was associated with an increase in intratumoral T reg -cell proliferation, as revealed by Ki67-BrdU (5bromodeoxyuridine) staining, reduced caspase-3-dependent programmed cell death, and increased expression of the anti-apoptotic protein Bcl2 (Fig. 4c-e and Supplementary Fig. 14c-e ). We also observed an Nrp1-dependent increase in the percentage of ICOS 1 , IL-10 1 and CD73 1 intratumoral T reg cells (Fig. 4f-h and Supplementary Fig. 14f-h) . Taken together, our data support a role for Nrp1 in modulating T regcell stability, survival and function in certain tumour microenvironments.
Our data demonstrate that cell contact-dependent potentiation of T reg -cell stability and function is mediated by Sema4a-Nrp1 ligation through a PTEN-Akt-Foxo axis ( Supplementary Fig. 15 ). This pathway enhances T reg -cell function indirectly by enforcing stability and promoting survival, and this is most evident in inflammatory sites such as certain tumours and colitic intestinal mucosa. However, Nrp1 signalling may also boost T reg -cell function directly by enhancing some suppressive mechanisms (for example, CD73). Apart from haematopoietic lineages, Sema4a seems to have a pattern of expression consistent with sites in which T reg -cell tolerogenic activity would be desired, such as the nervous system, eye and intestine 29 . The issue of T reg -cell stability has been highly contentious, and the mechanisms that maintain T regcell stability remain elusive [4] [5] [6] . As Foxo family members enhance Foxp3 function and promote T reg -cell homeostasis and function [26] [27] [28] , it is intriguing that Nrp1 signalling may counteract the negative impact of Akt on Foxo nuclear localization, resulting in substantial overlap between the transcriptional profiles induced by Foxo and Nrp1 signalling 28 . It is possible that the Nrp1-Sema4a pathway may be perturbed genetically or under certain pathologic circumstances; this could also provide a 
basis for the seemingly contradictory perceptions of T reg -cell stability in a variety of normal and diseased states. Previous studies have shown that plasmacytoid dendritic cells promote tolerance, T reg -cell differentiation and function, and their ablation has been shown to correlate with enhanced antitumour immunity 19, 30 . Given that the dominant intratumoral source of Sema4a was plasmacytoid dendritic cells, this raises the possibility that Nrp1-induced T regcell stability and survival provides a mechanistic explanation for these observations. As T reg cells represent a major barrier to anti-tumour immunity in many cancers, a clinically relevant and critical question is whether it is possible to limit T reg -cell function in tumours while preventing inflammatory or autoimmune adverse events. Recently, a role for Nrp1 in T reg cells was proposed to limit tumour growth in the MT/ ret murine melanoma model 29 , although contrary to the findings in that study we did not observe any differences in T reg -cell prevalence in B16 melanoma tumours (Fig. 2h) . However, further studies will be required to delineate in which tumours and under what conditions these two disparate functions of Nrp1 in T reg cells-regulation of T regcell migration and the maintenance of T reg -cell survival and stabilityare used. Our identification of Nrp1-Sema4a as a pivotal pathway required for intratumoral T reg -cell stability, but dispensable for the maintenance of immune homeostasis, suggests that Sema4a-Nrp1 blockade via antibodies or soluble antagonists may be a viable therapeutic strategy to limit tumour-induced tolerance without evoking autoimmunity.
METHODS SUMMARY
Mice. C57/BL6 and dnTGFßRII mice were purchased from the Jackson Laboratories. Foxp3 YFP-iCre , Foxp3and Foxp3 DTR-GFP mice were obtained from A.Y. Rudensky. Il10 -/mice were obtained from T. Geiger. Nrp1 f/f mice were obtained from D. Cheresh. Pten f/f 3 Foxp3 YFP-iCre mice were obtained from H. Chi. Animal experiments were performed in American Association for the Accreditation of Laboratory Animal Care-accredited, specific-pathogen-free facilities in the St Jude Animal Resource Center. Animal protocols were approved by the St Jude Animal Care and Use Committee.
METHODS
Mice. C57/BL6 and dnTGFßRII mice were purchased from the Jackson Laboratories. Foxp3 YFP-iCre , Foxp3and Foxp3 DTR-GFP mice were obtained from A.Y. Rudensky. Il10 -/mice were obtained from T. Geiger. Nrp1 f/f mice were obtained from D.
Cheresh. Pten f/f 3 Foxp3 YFP-iCre mice were obtained from H. Chi. Animal experiments were performed in American Association for the Accreditation of Laboratory Animal Care-accredited, specific-pathogen-free facilities in the St Jude Animal Resource Center. Animal protocols were approved by the St Jude Animal Care and Use Committee. Antibodies. Sema4a staining antibody was purchased from MBL (clone 5E3), and conjugated to biotin or Alexa Fluor 647 in-house. Polyclonal anti-Nrp1 was purchased from R&D Systems (AF566). Monoclonal antibodies were obtained from R&D Systems (Sema4a, 757129; Nrp1, 761704, MAB59941). Most flow cytometric antibodies were purchased from BioLegend. Anti-Foxp3 and anti-Eomes were purchased from eBioscience. KLF2 antibody was purchased from Millipore. Phospho-Akt (Ser473), phospho-S6K1 (Thr421-Ser424), Foxo3a, and pan Akt antibodies were purchased from Cell Signaling Technologies. PTEN-HRP (horseradish peroxidase) antibody was purchased from Santa Cruz Biotechnology. RNA interference. Control siRNA (catalogue no. 4390843) and pools of Sema4a (catalogue no. 4390771, siRNA no. s73547) siRNA were purchased from Life Technologies and resuspended per the manufacturer's instructions. CD4 1 and CD8 1 conventional T cells were sorted magnetically by negative selection and transfected by Amaxa (Lonza) with 300 pMol siRNA and 2 mg of pMaxGFP control plasmid, rested overnight in Amaxa nucleofector media. Cells were then sorted based on GFP, CD25, and CD45RB expression and co-cultured with T reg cells in the top well of a transwell suppression assay. Plasmids. Nrp1.mCherry was obtained from Addgene and used as a template to generate retroviral overexpresion constructs. Nrp1 WT was generated by adding the native signal sequence and cloned into pMICherry (MSCV-driven retroviral construct with an IRES-driven mCherry gene). Nrp1 DSEA was generated from the WT construct, deleting the terminal SEA motif by mutation of the serine codon to a stop codon. Akt WT , Akt DN (dominant-negative kinase dead K179M; described previously 23 Transwell suppression. 1.25 3 10 4 T reg cells purified flow cytometrically (CD4 1 CD45RB lo Foxp3 YFP-iCre1 ) were stimulated in the top chamber of a Millipore Millicell 96 (0.4 mm pore size) in the presence of flow cytometrically purified T conv cells (CD45RB hi CD25 -CD4 1 or CD8 1 ), B cells (B220 1 ), or T reg cells at a 1:4 ratio, Sema4a-IgG1-or IgG-conjugated latex beads (1:1 ratio), anti-CD3e (145.2C11) and anti-CD28 (37.51) conjugated latex beads (1:1 ratio), and/or neutralizing antibodies. In some experiments, the top well co-cultured cells were fixed with 2% paraformaldehyde for 15 min and washed extensively before co-culture with T reg cells. Purified T conv cells (5 3 10 4 ) were stimulated in the bottom well with anti-CD3-and anti-CD28-coated beads at a 1:1 ratio. Cells were cultured for 72 h and pulsed with 3 [H]-thymidine for the final 8 h. The bottom chambers were harvested and read with a beta counter.
For human studies, flow cytometrically purified umbilical cord blood T conv cells (CD4 1 CD25 -) and T reg cells (CD4 1 CD25 1 ) were activated with 3 mg ml 21 platebound anti-CD3 (clone OKT3), 2 mg ml 21 soluble anti-CD28 (clone CD28.1), and 100 units per ml rhIL-2 for 7-9 days. After collection and washing, T reg cells were stimulated at a 1:10 ratio with fixed autologous T conv -cell-or IgG-or Sema4a-IgG1coated latex beads in the top well of a transwell plate. 2.5 3 10 4 T conv cells were stimulated in the bottom well at a 1:1 ratio with OKT3-and CD28.1-coated latex beads. Cells were cultured for 5 d and pulsed with 3 [H]-thymidine for the final 8 h. The cells from the bottom chambers were collected and read with a beta counter. 'Transwell suppression' is defined as 100 -100 3 ((counts per min of a particular well) / (Average counts per min of unsuppressed cells)) to normalize across experiments. Fusion proteins. The sequence encoding the extracellular domains of Sema4a and Nrp1 were cloned in-frame to pX-Ig to create a Sema4a-or Nrp1-mouse IgG1 fusion protein construct (Sema4a-IgG1 and Nrp1-IgG1). J558L B cells were electroporated with this construct, and high-producing clones were selected by singlecell sorting. High-producing clones were seeded into Sartorious Bioreactors and collected for protein G purification and concentration. Sulphate latex 4-mm beads (Life Technologies) were conjugated with isotype control (mouse IgG1, MOPC21, R&D Systems) or Sema4a-Ig overnight with 3 pg protein per bead, blocked with 10% FBS, and stored in media. Mouse Sema-3a-Fc, Sema4a-Fc, mouse Nrp1, and human Sema4a-Fc was purchased from R&D Systems.
Binding assays. High protein binding ELISA plates were coated with 500 ng ml 21 recombinant murine Nrp1 (R&D Systems) overnight in PBS. After a 1-2-h block in 1% BSA in PBS at 4u in the dark, coated plates were incubated with various concentrations of Sema4a-IgG1 or mouse IgG1 for 2-4 h in the presence of anti-Sema4a, anti-Nrp1, or isotype control antibodies. Plates were then washed with PBS plus 0.05% Tween-20 10 times and incubated with 500 ng ml 21 biotinylated anti-mouse IgG1 antibody (BD Biosciences) to bind the fusion protein (or mouse IgG1 control). After 7 washes, Strepdavidin-HRP (GE Healthcare) was added at 500 ng ml 21 to detect the biotinylated antibody. After another 7 washes, TMB substrate (Thermo Scientific) was added and stopped with 1 N H 2 SO 4 .
For VEGF binding, the same protocol was followed, except that rather than Sema4a-IgG1 being used, VEGF 165 (R&D Systems) was used at 50 ng ml 21 in PBS and detected with 500 ng ml 21 anti-VEGF-biotin (R&D Systems) followed by SA-HRP for detection.
For comparisons across Sema family members, plates were coated with varying concentrations of Sema3a-Fc, Sema4d-Fc, Sema4a-IgG1, or isotype control overnight. Biotinylated Nrp1-IgG1 was added and incubated for 3 h, and SA-HRP was used for detection. mRNA analysis. RNA was extracted from cells lysed in TRIzol reagent (Life Technologies) and reverse transcribed with the High Capacity Reverse Transcription kit (Applied Biosystems). Real-time polymerase chain reaction (PCR) was carried out using primers and probes and TaqMan master mix or SYBR green chemistry (Applied Biosystems). Rescue of Foxp3-deficient autoimmunity. CD45.1 3 Foxp3 1/female mice were bred with CD45.1 male mice in timed breedings. Male progeny were genotyped at birth for Foxp3status. Purified Foxp3 Cre (1 3 10 6 ) or Nrp1 f/f Foxp3 Cre CD45.2 1 T reg cells, purified by flow cytometry, were injected intraperitoneally into Foxp3male pups within 3 days of birth. Mice were monitored for the scurfy phenotype (scaly skin, eye inflammation, runted phenotype, and lack of mobility). For some experiments, all mice were killed at 5 weeks for histological analysis of the ear pinna, liver and lung. Tumour models. Foxp3 Cre , Nrp1 f/f Foxp3 Cre , or Foxp3 DTR-GFP mice were injected with B16.F10 melanoma (1.25 3 10 5 cells intradermally), EL4 thymoma (1.25 3 10 5 cells intradermally), or MC38 colon carcinoma (2.5 3 10 5 cells subcutaneously). Tumours were measured regularly with digital calipers and tumour volumes were calculated; this was done blind but not randomized. Tumours and lymph nodes were collected for analysis. TILs were prepared using a Percoll gradient from tumour samples after mechanical disruption. For metastasis studies, B16.F10 was injected intravenously at various doses. After 17-20 days, lungs were harvested, inflated with H 2 O 2 , and metastases were counted. Therapeutic B16 experiments were conducted by injecting 1.25 3 10 5 B16 melanoma cells intradermally and waiting until tumours were palpable (5 days). On day 5, mice began to receive intraperitoneal injections of either rat IgG2a, or anti-Nrp1 (R&D Systems clone 761704, MAB59941) (400 mg initial dose and 200 mg every 3 days). Prophylactic experiments included anti-Sema4a (R&D Systems clone 757129) and Sema4a-IgG1 consisting of twice weekly injections of 100 mg of protein starting on the day of tumour inoculation. To achieve reasonable power, at least 15 mice were used in each group, at least 5 mice per experiment. Additional mice were added to experiments as appropriate. Experimental colitis. Six-to eight-week-old RAG2 2/2 mice were injected intraperitoneally with 4 3 10 5 congenically marked CD45RB hi CD25 -T conv cells. When the majority of the mice had lost 10% body weight and had colitis symptoms (21 to 28 days later), 13 10 6 Foxp3 Cre or Nrp1 f/f Foxp3 Cre T reg cells were injected intraperitoneally. Mice that did not lose 10% body weight at this time received no injection and were excluded from analysis, and mice received randomized injections (different genotypes of transferred cells per cage). Body weight was measured daily in a blinded fashion, and 28 days after T reg -cell rescue, sections were stained for histology. To achieve reasonable power, at least 15 mice were used in each group, and at least 5 mice per experiment. Additional mice were added to experiments as appropriate. Signalling analysis. For flow cytometry, T reg cells were stimulated with anti-CD3and anti-CD28-coated beads and IgG1-coated or Sema4a-IgG1-coated beads overnight, then fixed with 1% PFA for 15 min at 37 uC. Cells were then permeabilized in ice-cold 90% MeOH for 20 min at 220 uC. After extensive washing in PBS, cells were blocked with 10% normal mouse serum in PBS for 10 min at room temperature. Cells were then stained with antibodies in 1% BSA in PBS (phosphorylated S6K1 (pS6K1) (Thr421-Ser424), pAkt (Ser473), or pAkt (Thr308)) for 1 h at room temperature, in the dark. Finally, cells were stained with appropriate secondary antibodies for 30 min at room temperature, in the dark, then washed and analysed. For immunoblot analysis, T reg cells were expanded with 1 ng ml 21 phorbol-13myristol acetate and 10 ng ml 21 ionomycin with 500 units recombinant human interleukin-2 (IL-2) for 3 days, then washed extensively with media, and expanded to 103 volume in 500 units recombinant human IL-2. After an overnight rest with no IL-2, T reg cells were stimulated with plate-bound anti-CD3, soluble anti-CD28, LETTER RESEARCH
